Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Completed

• Conditions: Lymphoma, B-Cell

• Registration Number: NCT05133505
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01-01
• Primary Completion: 2021-10-01
• Status Verified: 2021-11
• Study Completion: 2021-11-01
• Study First Submitted: 2021-11-12
• Study First Submitted QC: 2021-11-12
• Last Update Submitted: 2021-11-12
• Study First Posted: 2021-11-24
• Last Update Posted: 2021-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TIM-3 and Gal-9 immunohistochemical expression	1 day	TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells

Trial Locations

Locations (1)

Uh Montpellier; 🇫🇷 Montpellier, France